Niagen Bioscience raises FY25 revenue view to up 25%-30% from up 22%-27%

“Elevating NAD+ is critical for health, especially as we age, and greater attention to this important area of science is valuable for public health and for Niagen Bioscience (NAGE),” remarked Rob Fried, CEO of Niagen Bioscience. “We believe the FDA’s latest reversal of previous rulings on the DSHEA drug preclusion rule relating to NMN could serve to increase awareness of the NAD+ precursor market overall and the safety and efficacy of Niagen, in particular. Also, it is important to note that NMN products being sold on the market infringe upon an existing patent portfolio.”